PT1966214T - Triazolpiridazinas como moduladores de tirosina quinase - Google Patents

Triazolpiridazinas como moduladores de tirosina quinase

Info

Publication number
PT1966214T
PT1966214T PT68477496T PT06847749T PT1966214T PT 1966214 T PT1966214 T PT 1966214T PT 68477496 T PT68477496 T PT 68477496T PT 06847749 T PT06847749 T PT 06847749T PT 1966214 T PT1966214 T PT 1966214T
Authority
PT
Portugal
Prior art keywords
triazolopyridazines
tyrosine kinase
kinase modulators
modulators
tyrosine
Prior art date
Application number
PT68477496T
Other languages
English (en)
Inventor
D Cummings Maxwell
Lu Tianbao
Alexander Richard
W Connors Richard
A Galemmo Robert
Rae Hufnagel Heather
L Johnson Dana
Khalil Ehab
A Leonard Kristi
P Markotan Thomas
C Maroney Anna
L Sechler Jan
M Travins Jeremy
W Tuman Robert
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37964498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1966214(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PT1966214T publication Critical patent/PT1966214T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT68477496T 2005-12-21 2006-12-18 Triazolpiridazinas como moduladores de tirosina quinase PT1966214T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75263405P 2005-12-21 2005-12-21

Publications (1)

Publication Number Publication Date
PT1966214T true PT1966214T (pt) 2017-02-03

Family

ID=37964498

Family Applications (1)

Application Number Title Priority Date Filing Date
PT68477496T PT1966214T (pt) 2005-12-21 2006-12-18 Triazolpiridazinas como moduladores de tirosina quinase

Country Status (40)

Country Link
US (2) US8030305B2 (pt)
EP (1) EP1966214B9 (pt)
JP (1) JP5292102B2 (pt)
KR (1) KR101412675B1 (pt)
CN (1) CN101374843B (pt)
AP (1) AP3433A (pt)
AR (1) AR058703A1 (pt)
AU (1) AU2006331912B2 (pt)
BR (1) BRPI0620292B1 (pt)
CA (1) CA2634721C (pt)
CR (1) CR10170A (pt)
CY (1) CY1118846T1 (pt)
DK (1) DK1966214T3 (pt)
EA (1) EA015754B1 (pt)
EC (1) ECSP088573A (pt)
ES (1) ES2612377T3 (pt)
GT (1) GT200800105A (pt)
HN (1) HN2008000931A (pt)
HR (1) HRP20170103T1 (pt)
HU (1) HUE030390T2 (pt)
IL (1) IL192108A (pt)
LT (1) LT1966214T (pt)
MA (1) MA30084B1 (pt)
ME (1) ME02736B (pt)
MX (1) MX2008008277A (pt)
MY (1) MY159523A (pt)
NI (1) NI200800179A (pt)
NO (1) NO340958B1 (pt)
NZ (1) NZ568807A (pt)
PE (2) PE20070752A1 (pt)
PL (1) PL1966214T3 (pt)
PT (1) PT1966214T (pt)
RS (1) RS55630B1 (pt)
SV (1) SV2008002963A (pt)
TN (1) TNSN08278A1 (pt)
TW (1) TWI399378B (pt)
UA (1) UA98297C2 (pt)
UY (1) UY30041A1 (pt)
WO (1) WO2007075567A1 (pt)
ZA (1) ZA200806277B (pt)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2588180A1 (en) * 2004-12-17 2006-06-22 Bionovo, Inc. Method of using extracts of epimedium species
US7482029B2 (en) 2005-04-01 2009-01-27 Bionovo, Inc. Composition for treatment of menopause
US7700136B2 (en) * 2005-11-14 2010-04-20 Bionovo, Inc. Scutellaria barbata extract for the treatment of cancer
JP5144532B2 (ja) * 2005-11-30 2013-02-13 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−Ｍｅｔ阻害剤及び用法
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
EP3327016B1 (en) 2006-04-07 2021-06-16 Vertex Pharmaceuticals Incorporated Preparation of modulators of atp-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
WO2007138472A2 (en) * 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
EP2057164A1 (en) 2006-08-07 2009-05-13 Incyte Corporation Triazolotriazines as kinase inhibitors
AU2007309237B2 (en) * 2006-10-23 2012-03-22 Sgx Pharmaceuticals, Inc. Triazolo-pyridazine protein kinase modulators
EP2089710B1 (en) 2006-10-27 2014-10-01 Janssen Pharmaceutica NV A method for pharmacologically profiling compounds
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
ME01507B (me) 2006-11-22 2014-04-20 Incyte Holdings Corp Imidazotriazini i imidazopirimidini kao inhibitori kinaze
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
JP5548123B2 (ja) 2007-06-21 2014-07-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ６−｛ジフルオロ［６−（１−メチル−１Ｈ−ピラゾル−４−イル）［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン−３−イル］メチル｝キノリンの多形および水和物の形態、塩、ならびに製造方法
US20090042818A1 (en) * 2007-06-22 2009-02-12 Bionovo, Inc. Liquiritigenin and Derivatives as Selective Estrogen Receptor Beta Agonists
US20080319051A1 (en) * 2007-06-22 2008-12-25 Bionovo, Inc. Liquiritigenin and derivatives as selective estrogen receptor beta agonists
EP2170337A4 (en) 2007-06-28 2013-12-18 Abbvie Inc NEW TRIAZOLOPYRIDAZINE
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
AU2008285325A1 (en) * 2007-08-08 2009-02-12 Bionovo, Inc. Extracts of Ligustrum lucidum and uses thereof
FR2919870B1 (fr) * 2007-08-09 2014-05-16 Sanofi Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
PA8792501A1 (es) * 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
FR2929613B1 (fr) * 2008-04-02 2010-12-31 Sanofi Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met
DE102007038957A1 (de) * 2007-08-17 2009-02-19 Merck Patent Gmbh 6-Thioxo-pyridazinderivate
EP2194998A4 (en) * 2007-09-07 2012-03-21 Bionovo Inc STROGENIC EXTRACTS OF ASPARAGUS CONCHINCHINENSIS (LOUR.) MERR OF THE LILIACEAE FAMILY AND USES THEREOF
US9155770B2 (en) * 2007-09-07 2015-10-13 Bionovo, Inc. Estrogenic extracts of Scuttelaria barbata D. don of the labiatae family and uses thereof
US20090068298A1 (en) * 2007-09-07 2009-03-12 Bionovo, Inc. ESTROGENIC EXTRACTS OF Astragalus membranaceus Fisch. Bge. Var. mongolicus Bge. of the Leguminosae Family AND USES THEREOF
EP2203178A4 (en) * 2007-09-07 2012-03-21 Bionovo Inc ESTROGENEXTRACTS FROM PUERARIA LOBATA WILLD, OHWI FROM THE FAMILY OF LEGUMINOSAE AND APPLICATIONS THEREOF
AU2008329902A1 (en) * 2007-11-19 2009-06-04 Bionovo, Inc. A process of making purified extract of scutellaria barbata D. Don
CA2706326A1 (en) * 2007-11-19 2009-05-28 Bionovo, Inc. Scutellaria barbata extract and combinations for the treatment of cancer
WO2009067550A1 (en) * 2007-11-19 2009-05-28 Bionovo, Inc. Methods of detecting and treatment of cancers using scuttelaria barbata extract
AU2008326429A1 (en) * 2007-11-19 2009-05-28 Bionovo, Inc. Anti-cancer therapy with an extract of scutellaria barbata
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
CN101980710B (zh) * 2008-02-05 2013-07-31 赛诺菲-安万特 作为par1抑制剂的咪唑并哒嗪、其制备及其作为药物的用途
AU2009211887B2 (en) * 2008-02-05 2013-09-19 Sanofi Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments
PL2240486T3 (pl) * 2008-02-05 2016-02-29 Sanofi Sa Sole triazoliowe jako inhibitory PAR1, ich wytwarzanie i zastosowanie jako lek
WO2009106577A1 (en) 2008-02-28 2009-09-03 Novartis Ag Imidazo [1,2-b] pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
EP2276480A4 (en) * 2008-04-14 2011-08-10 Bionovo Inc CALYCOSINE AND ITS ANALOGUE FOR THE TREATMENT OF ESTROGEN RECEPTOR-BETA-MEDIATED ILLNESSES
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
CA2723403A1 (en) * 2008-05-06 2009-11-12 Bionovo, Inc. Estrogenic extracts for use in treating vaginal and vulvar atrophy
BRPI0912882A2 (pt) 2008-05-21 2017-05-16 Incyte Corp sais de 2-flúor-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida e processos relacionados à preparação dos mesmos
CA2726982A1 (en) * 2008-06-05 2009-12-10 Bionovo, Inc. Method of quantification of multiple bioactives from botanical compositions
CA2727018A1 (en) * 2008-06-06 2009-12-10 Bionovo, Inc. Anthraquinones and analogs from rhuem palmatum for treatment of estrogen receptor beta-mediated conditions
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
FR2941229B1 (fr) * 2009-01-21 2012-11-30 Sanofi Aventis Nouveaux derives triazolo°4,3-a!pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
KR20110039558A (ko) * 2008-07-18 2011-04-19 사노피-아벤티스 신규 트리아졸로(4,3-ａ)피리딘 유도체, 그의 제조 방법, 의약으로서의 그의 용도, 제약 조성물, 및 특히 ｍｅｔ 억제제로서의 신규 용도
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
UY32049A (es) * 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
DE102008037790A1 (de) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
WO2010028187A2 (en) * 2008-09-03 2010-03-11 Bionovo, Inc. Methods and compositions for the treatment of cancer
WO2010059771A1 (en) 2008-11-20 2010-05-27 Osi Pharmaceuticals, Inc. Substituted pyrrolo[2,3-b]-pyridines and-pyrazines
DE102008063667A1 (de) 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
PT2361250E (pt) 2008-12-22 2013-11-11 Merck Patent Gmbh Novas formas polimórficas de di-hidrogenofosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-benzil}-2h-piridazin-3-ona e processos de fabrico das mesmas
DE102008062825A1 (de) 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
CA2754180A1 (en) 2009-03-09 2010-09-16 The Regents Of The University Of California Substituted heterocycles and their use as allosteric modulators of nicotinic and gabaa receptors
EP2424555A4 (en) * 2009-04-28 2013-02-20 Bionovo Inc METHOD FOR REDUCING FAT COLLECTION AND CAUSING WEIGHT LOSS
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
CN102548995B (zh) * 2009-08-12 2015-01-28 诺华股份有限公司 杂环腙化合物以及它们治疗癌症和炎症的用途
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
KR20120089463A (ko) 2009-08-20 2012-08-10 노파르티스 아게 헤테로시클릭 옥심 화합물
DE102009056886A1 (de) * 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
SG181781A1 (en) 2009-12-31 2012-07-30 Hutchison Medipharma Ltd Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
WO2011162835A1 (en) 2010-02-03 2011-12-29 Incyte Corporation Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
EP2560954B1 (en) * 2010-04-22 2016-10-05 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
WO2011143646A1 (en) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
WO2012003338A1 (en) 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
KR101538707B1 (ko) * 2010-07-14 2015-07-22 베타 파머수티컬 컴퍼니 리미티드 c-MET 티로신 키나제 억제제로서 유용한 신규 융합된 헤테로사이클릭 유도체
JP5996532B2 (ja) 2010-07-15 2016-09-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 有害生物防除剤としての新規複素環式化合物
US9309322B2 (en) 2010-11-12 2016-04-12 Scott & White Healthcare (Swh) Antibodies to tumor endothelial marker 8
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
EP2710003A1 (en) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
CN103958509B (zh) * 2011-09-15 2015-12-23 诺华股份有限公司 作为酪氨酸激酶抑制剂的6-取代的3-(喹啉-6-基硫代)-[1,2,4]三唑并[4,3-a]吡啶化合物
JP5957526B2 (ja) 2011-09-15 2016-07-27 ノバルティス アーゲー チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
CN102516263B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种螺三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN102503959B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种稠三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
KR20130091464A (ko) * 2012-02-08 2013-08-19 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체
KR101869534B1 (ko) * 2012-03-05 2018-06-20 한국화학연구원 신규한 트리아졸로 피리다진 유도체 및 그의 용도
CN104244982A (zh) 2012-04-03 2014-12-24 诺华股份有限公司 酪氨酸激酶抑制剂组合及其用途
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
WO2014014841A1 (en) 2012-07-16 2014-01-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
CA2880178C (en) * 2012-07-27 2021-10-26 Sato Pharmaceutical Co., Ltd. Difluoromethylene compound
CN103122000B (zh) 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
US9422290B2 (en) 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
CN104250257B (zh) * 2013-06-25 2017-06-16 上海翰森生物医药科技有限公司 3,4‑二氢‑1H‑苯并[c][1,2]噁硼酸类化合物或其可药用盐及其制备方法和用途
CN103524431B (zh) * 2013-09-24 2016-01-13 西安交通大学 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用
GB201321745D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
SI3122358T1 (sl) 2014-03-26 2021-04-30 Astex Therapeutics Ltd. Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
WO2015144808A1 (en) 2014-03-26 2015-10-01 Astex Therapeutics Ltd Combinations of an fgfr inhibitor and an igf1r inhibitor
JP6543268B2 (ja) 2014-04-15 2019-07-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンス調節因子が媒介する疾患を処置するための医薬組成物
TWI695837B (zh) 2014-12-04 2020-06-11 比利時商健生藥品公司 作為激酶調節劑之三唑並嗒
ES2764299T3 (es) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
SG11201704763SA (en) * 2014-12-11 2017-07-28 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN106279176B (zh) * 2015-06-11 2020-09-08 中国科学院上海药物研究所 氘代的3-[(6-喹啉基)二氟甲基]-6-[(1-甲基)-4-吡唑基][1,2,4]三唑并[4,3-b]哒嗪及其应用
KR20180019234A (ko) 2015-06-26 2018-02-23 다케다 야쿠힌 고교 가부시키가이샤 콜린성 무스카린 m1 수용체의 조절제로서의 2,3-디히드로-4h-1,3-벤족사진-4-온 유도체
KR20180052631A (ko) 2015-09-23 2018-05-18 얀센 파마슈티카 엔.브이. 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도
CN108026095B (zh) 2015-09-23 2021-07-27 詹森药业有限公司 新化合物
CN105272995B (zh) * 2015-09-24 2017-10-27 上海海聚生物科技有限公司 喹啉类衍生物、其药物组合物、制备方法及应用
US10548899B2 (en) 2015-10-20 2020-02-04 Takeda Pharmaceutical Company Limited Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity
CN108853108A (zh) * 2015-12-31 2018-11-23 北京浦润奥生物科技有限责任公司 化合物在制备用于治疗脑胶质瘤的药物中的用途
BR112019003174B1 (pt) 2016-08-16 2022-10-25 Bayer Cropscience Aktiengesellschaft Processo para preparar derivados de 2-(3,6-dihalopiridin-2-il)-3h-imidazol[4,5-c]piridina, e seus intermediários
CN110337295B (zh) 2016-11-28 2023-06-09 普拉克西斯精密药物股份有限公司 化合物以及它们的使用方法
US11261188B2 (en) 2016-11-28 2022-03-01 Praxis Precision Medicines, Inc. Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11731966B2 (en) 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
TWI774755B (zh) * 2017-04-28 2022-08-21 日商佐藤製藥股份有限公司 二氟甲烯化合物之製造法
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
EP3781551A1 (en) * 2018-04-18 2021-02-24 Basf Se D-glucaro-6,3-lactone monoester and a process for the preparation thereof
CN112423760A (zh) * 2018-05-30 2021-02-26 普拉克西斯精密药物股份有限公司 离子通道调节剂
CN109045036B (zh) * 2018-07-19 2020-10-02 中山大学 [1,2,4]三唑并[4,3-b]哒嗪衍生物在制备抗肿瘤药物中的应用
WO2020124060A1 (en) 2018-12-14 2020-06-18 Beta Pharma, Inc. Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN110156805B (zh) * 2019-05-22 2020-12-11 南京合巨药业有限公司 一种2, 3-二氢-1, 4-二氧代[2,3-b]吡啶-7-羧酸的制备方法
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
US20230338294A1 (en) * 2020-04-26 2023-10-26 Apollomics Inc. Novel pharmaceutical formulation for c-met inhibitor
TWI728882B (zh) 2020-07-28 2021-05-21 祥昇機電工業有限公司 自吸式抽水機之釋氣機構
WO2024032647A1 (zh) * 2022-08-09 2024-02-15 上海济煜医药科技有限公司 含氮杂环化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US96322A (en) * 1869-11-02 Improvement in combined cultivator and seed-planter
US138264A (en) * 1873-04-29 Improvement in machines for cutting out planchets of sheet metal
US17309A (en) * 1857-05-12 Portable gas co
US261297A (en) * 1882-07-18 Mortar for stamp-mills
US147568A (en) * 1874-02-17 Improvement in paper-folding attachments for printing-presses
US192696A (en) * 1877-07-03 Improvement in combined cut-off and filter
US171798A (en) * 1876-01-04 Improvement in spring attachments for cradles
US111495A (en) * 1871-01-31 Stinb
US181455A (en) * 1876-08-22 Improvement in brooms
US16625A (en) * 1857-02-10 Arraitg-ement of springs for vehicles
NL128591C (pt) * 1965-07-02
NL130097C (pt) 1966-10-22
US3506656A (en) * 1966-10-22 1970-04-14 Boehringer Mannheim Gmbh Triazolo-tetrazolo-pyridazine derivatives
DE2222834A1 (de) 1972-05-10 1973-11-29 Boehringer Mannheim Gmbh Nitrofuryl-amidin-derivate und verfahren zur herstellung derselben
US3823137A (en) * 1970-06-20 1974-07-09 Boehringer Mannheim Gmbh Novel nitrofuran compounds and pharmaceutical compositions
DE2030581A1 (de) 1970-06-20 1971-12-30 Boehringer Mannheim GmbH, 6800 Mannheim-Waldhof Nitrofuryl-amidin-Derivate und Verfahren zur Herstellung derselben
DE2161587A1 (de) 1971-12-11 1973-06-14 Boehringer Mannheim Gmbh Nitrofuryl-triazolo eckige klammer auf 4,3-b eckige klammer zu pyridazinderivat
GB1324060A (en) 1971-03-19 1973-07-18 Boehringer Mannheim Gmbh Nitrofuryl-triazolo 4,3-b pyridazine derivatives
DE2113438A1 (de) 1971-03-19 1972-09-21 Boehringer Mannheim Gmbh Nitrofuryl-triazolo[4,3-b]pyridazinderivate
DE2147013A1 (de) 1971-09-21 1973-03-29 Boehringer Mannheim Gmbh Antimikrobiell wirksame nitrofuranderivate und verfahren zur herstellung derselben
JPS5612390A (en) * 1979-07-10 1981-02-06 Yoshitomi Pharmaceut Ind Ltd Triazolopyridazine derivative
US4260755A (en) * 1979-10-31 1981-04-07 American Cyanamid Company Novel 6-phenyl and substituted 6-phenyl-1,2,4-triazolo[4,3-b]pyridazines
FR2562071B1 (fr) * 1984-03-30 1986-12-19 Sanofi Sa Triazolo(4,3-b)pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant
JPS63199347A (ja) 1987-02-14 1988-08-17 Konica Corp 鮮鋭性の向上した高感度ハロゲン化銀写真感光材料
JPS63310891A (ja) 1987-06-12 1988-12-19 Yoshitomi Pharmaceut Ind Ltd 縮合ピリダジン化合物
AU622330B2 (en) 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
CA2044564A1 (en) 1990-06-28 1991-12-29 Quirico Branca Amino acid derivatives
US5278161A (en) * 1990-06-28 1994-01-11 Hoffmann-La Roche Inc. Amino acid derivatives useful as renin inhibitors
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
DE4309285A1 (de) 1993-03-23 1994-09-29 Boehringer Ingelheim Kg Heterocyclen enthaltende Amidinderivate, ihre Herstellung und Verwendung
JPH06331089A (ja) 1993-05-18 1994-11-29 Asahi Organic Chem Ind Co Ltd プラスチック管の電気溶着方法
TW304878B (pt) 1993-09-21 1997-05-11 Takeda Pharm Industry Co Ltd
KR19990007865A (ko) 1995-04-19 1999-01-25 스피겔알렌제이 약물 방출용 피복 스텐트
US20020111495A1 (en) * 1997-04-04 2002-08-15 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
GB9718254D0 (en) * 1997-08-28 1997-11-05 Merck Sharp & Dohme Therapeutic agents
US6297235B1 (en) * 1997-08-28 2001-10-02 Merck Sharp & Dohme Ltd. Triazolopyridazine derivatives for treating anxiety and enhancing cognition
GB9801208D0 (en) * 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
NZ504870A (en) * 1998-01-21 2002-11-26 Merck Sharp & Dohme Triazolo-pyridazine derivatives as ligands for gaba receptors
GB9801538D0 (en) 1998-01-23 1998-03-25 Merck Sharp & Dohme Pharmaceutical product
GB9816654D0 (en) 1998-07-30 1998-09-30 Zeneca Ltd Chemical compounds
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
AU1481701A (en) 1999-11-12 2001-06-06 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
DE10038019A1 (de) 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
ES2239203T3 (es) 2001-01-31 2005-09-16 Pfizer Products Inc. Derivados nicotinamida y sus mimeticos como inhibidores de isozimas pde4.
US7250518B2 (en) * 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
US7186720B2 (en) * 2001-04-20 2007-03-06 Sanofi-Aventis Tetrahydropyridyl-alkyl-heterocycles, method for preparing the same and pharmaceutical compositions containing the same
JP2005509616A (ja) 2001-10-16 2005-04-14 センジェント・セラピューティクス・インク チロシンホスファターゼに対する有機硫黄阻害剤
AU2003211424A1 (en) * 2002-03-01 2003-09-16 Yamanouchi Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compound
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
US6793457B2 (en) * 2002-11-15 2004-09-21 General Electric Company Fabricated repair of cast nozzle
AU2003297161B8 (en) * 2002-12-18 2011-03-31 Vertex Pharmaceuticals Incorporated Triazolopyridazines as protein kinases inhibitors
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
JPWO2005002590A1 (ja) 2003-07-01 2006-08-10 アステラス製薬株式会社 骨量増加誘導剤
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
US7037909B2 (en) 2003-07-02 2006-05-02 Sugen, Inc. Tetracyclic compounds as c-Met inhibitors
WO2005004607A1 (en) * 2003-07-02 2005-01-20 Sugen, Inc. Arylmethyl triazolo and imidazopyrazines as c-met inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
JP5144532B2 (ja) * 2005-11-30 2013-02-13 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−Ｍｅｔ阻害剤及び用法
WO2007138472A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met

Also Published As

Publication number Publication date
MA30084B1 (fr) 2008-12-01
EP1966214B9 (en) 2017-09-13
LT1966214T (lt) 2017-02-10
IL192108A0 (en) 2008-12-29
DK1966214T3 (en) 2017-02-13
CY1118846T1 (el) 2018-01-10
KR20080085154A (ko) 2008-09-23
BRPI0620292A2 (pt) 2011-11-08
ZA200806277B (en) 2010-09-29
US20070203136A1 (en) 2007-08-30
HN2008000931A (es) 2013-10-22
SV2008002963A (es) 2010-01-18
PL1966214T3 (pl) 2017-04-28
AP2008004502A0 (en) 2008-06-30
EA015754B1 (ru) 2011-12-30
TWI399378B (zh) 2013-06-21
AU2006331912B2 (en) 2012-08-30
ME02736B (me) 2017-10-20
PE20110008A1 (es) 2011-01-31
RS55630B1 (sr) 2017-06-30
US20090098181A1 (en) 2009-04-16
KR101412675B1 (ko) 2014-07-03
MY159523A (en) 2017-01-13
TNSN08278A1 (en) 2009-10-30
NZ568807A (en) 2011-05-27
US8173654B2 (en) 2012-05-08
HUE030390T2 (en) 2017-05-29
UA98297C2 (en) 2012-05-10
JP5292102B2 (ja) 2013-09-18
ECSP088573A (es) 2008-07-30
PE20070752A1 (es) 2007-08-13
WO2007075567A1 (en) 2007-07-05
AR058703A1 (es) 2008-02-20
AU2006331912A1 (en) 2007-07-05
NI200800179A (es) 2016-01-06
AP3433A (en) 2015-10-31
MX2008008277A (es) 2009-03-04
HRP20170103T1 (hr) 2017-03-24
ES2612377T3 (es) 2017-05-16
CA2634721A1 (en) 2007-07-05
EA200870085A1 (ru) 2008-12-30
CA2634721C (en) 2014-06-17
EP1966214B1 (en) 2016-11-02
UY30041A1 (es) 2007-05-31
NO340958B1 (no) 2017-07-31
NO20083013L (no) 2008-09-19
US8030305B2 (en) 2011-10-04
CN101374843A (zh) 2009-02-25
CN101374843B (zh) 2012-09-05
JP2009525263A (ja) 2009-07-09
IL192108A (en) 2014-02-27
TW200801007A (en) 2008-01-01
BRPI0620292B1 (pt) 2021-08-24
EP1966214A1 (en) 2008-09-10
GT200800105A (es) 2008-10-10
CR10170A (es) 2008-11-24

Similar Documents

Publication Publication Date Title
ZA200806277B (en) Triazolopyridazines as tyrosine kinase modulators
HK1116059A1 (en) Aminopyrimidines as kinase modulators
IL187693A0 (en) Aminopyrimidines as kinase modulators
IL180790A0 (en) Pyrrolo-pyridine kinase modulators
HK1114380A1 (en) Pyrrolopyrazoles as kinase inhibitors
GB2434642B (en) Optical authentication
IL186845A0 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
IL197015A0 (en) Benzotriazole kinase modulators
IL184657A0 (en) Adam-9 modulators
IL191880A0 (en) Compounds having cytokine modulating properties
IL187692A0 (en) Alkylquinoline and alkylquinazoline kinase modulators
IL189846A0 (en) Theramutein modulators
EP1874674A4 (en) liquid plug
EP1915162A4 (en) MODULATORS
SI1896422T1 (sl) Tirosin kinazni inhibitorji
GB0526422D0 (en) Authentication
EP1951252A4 (en) INHIBITORS OF TYROSINE KINASES
ZA200801986B (en) Standard
GB0405985D0 (en) Kinase
ZA200710136B (en) Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
ZA200800274B (en) Aminopyrimidines as kinase modulators
ZA200800275B (en) Aminopyrimidines as kinase modulators
ZA200709732B (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
GB0517246D0 (en) Prioritisation scheme
GB0603829D0 (en) No knots